BioCentury
ARTICLE | Emerging Company Profile

PepGen: $112.5M round for cell-penetrating oligos and a Boston build-out

Emerging Company Profile: PepGen’s crossover round to take at least two muscular dystrophy assets into the clinic

August 6, 2021 12:53 AM UTC

With a fresh $112.5 million in crossover funding, PepGen is prepared to take at least two muscular dystrophy therapies into the clinic by 2023 and build out a new headquarters in Boston. 

Thursday’s venture round included backing from existing investors RA Capital Management, Oxford Sciences Innovation (OSI) and CureDuchenne Ventures, and added eight disclosed new investors. The round’s large number of crossover investors signals a potential IPO on the horizon...

BCIQ Company Profiles

PepGen Inc.